{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-006600","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2024-01-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.996854+00:00","generated_at":"2026-06-07T00:45:14.951350+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Heron partners with CrossLink to add ~650 sales reps for ZYNRELEF through 2028","bullets":["CrossLink adds at least 325 sales reps by July 2024 and 650 by Jan 2025.","Fixed-fee per vial compensation based on growth over baseline period.","Up to 1,666,670 shares of common stock and $5M in milestone payments.","Five-year term ending Dec 2028, renewable annually.","Partnership targets orthopedic indications; initial regional rollout expands nationally."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-006600","json":"https://secwatch.observer/filing/0001193125-24-006600.json","markdown":"https://secwatch.observer/filing/0001193125-24-006600.md","text":"https://secwatch.observer/filing/0001193125-24-006600.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000119312524006600/0001193125-24-006600-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000119312524006600/d636605d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T00:45:14.951350+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fbf2e0c11c810d633a523c3ead6177d5699035bc","claim":"HERON THERAPEUTICS, INC. /DE/ entered into Co-Promotion Agreement with Crosslink Network, LLC valued at Up to 1,666,670 shares of common stock; cash base compensation on fixed-fee per vial basis; up to $5 (effective 2024-01-05).","evidence_excerpt":"On January 5, 2024, Heron Therapeutics, Inc. (the “Company”) and Crosslink Network, LLC (“Crosslink”) entered into a Co-Promotion Agreement (the “Co-Promotion Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818033/000119312524006600/0001193125-24-006600-index.htm","confidence":0.98,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Crosslink Network, LLC"},{"label":"Value","value":"Up to 1,666,670 shares of common stock; cash base compensation on fixed-fee per vial basis; up to $5"},{"label":"Effective","value":"2024-01-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}